OptiBiotix Health PLC (LON:OPTI) CEO Stephen OHara caught up with DirectorsTalk to share his thoughts on an article discussing Why Pharma Insiders Are Betting £100m On “the Microbiome”. The article points out that a French group Seventure Partners has raised over £100m for a new fund, Health For Life, ‘the first investment vehicle in the world to anticipate the microbiome revolution in the fields of health and nutrition.’
CEO Isabelle de Cremoux, explains ‘Since the bitechnology sector started in the 1980s, we are now witnessing the emergence of a new sector that will be as important as genomics… The microbiome revolution will have an impact in the veterinary and agricultural fields as well as in human healthcare… Worldwide pharmaceutical groups are increasingly interested in the microbiome field as a means of finding new ways to conduct research and to develop drugs with accompanying diagnostics, especially for infectious and gastrointestinal diseases…….’
Stephen OHara, OptiBiotix Health Plc CEO said: ‘This article touches on the increasing number of opportunities provided by the microbiome to impact on health. OptBiotix is leading the field in this evolving market forecast to become one of the world’s fastest growth areas in the next 10 years. In the last 12 months OptiBiotix has strengthened its IP, validated its technology platforms, and gained 6 commercial deals building a company with substantive IP and knowhow in many of the major lifestyle diseases (e.g obesity, cardiovascular diseases, diabetes) impacting on human health today’.
